Provided by Tiger Trade Technology Pte. Ltd.

Evolus Inc.

7.14
-0.5500-7.15%
Post-market: 7.140.00000.00%19:30 EDT
Volume:2.07M
Turnover:14.97M
Market Cap:470.20M
PE:-13.56
High:7.72
Open:7.72
Low:6.91
Close:7.69
52wk High:9.31
52wk Low:3.86
Shares:65.85M
Float Shares:47.53M
Volume Ratio:3.65
T/O Rate:4.36%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.5267
EPS(LYR):-0.8010
ROE:-18729.61%
ROA:-5.68%
PB:-15.22
PE(LYR):-8.91

Loading ...

Evolus Outlook FY Sales Growth 11-13%

THOMSON REUTERS
·
Aug 06

Evolus Outlook FY Sales USD 330-337 Million

THOMSON REUTERS
·
Aug 06

Evolus expands strategic partnership with Symatese to commercialize Estyme

TIPRANKS
·
Aug 04

Evolus Expands Symatese Partnership to Commercialize Estyme HA Gels in Canada, Australia, New Zealand

Reuters
·
Aug 04

Evolus Expands Strategic Partnership with Symatese to Commercialize Estyme® in Canada, Australia, and New Zealand

THOMSON REUTERS
·
Aug 04

Evolus - Agreement Expected to be Accretive to Evolus International Gross Margins

THOMSON REUTERS
·
Aug 04

Evolus - to Commercialize Estyme in All Markets with Jeuveau and Nuceiva in 2028

THOMSON REUTERS
·
Aug 04

Evolus - to Pay Upfront, Milestone Payments and Mid-Single Digit Royalty to Symatese

THOMSON REUTERS
·
Aug 04

Evolus Inc Expected to Post a Loss of 3 Cents a Share - Earnings Preview

Reuters
·
Aug 04

Evolus to Report Second-quarter Results After Markets Close, Host Conference Call

Reuters
·
Jul 22

Evolus Reports 115,000 RSU Inducement Grants to 38 New Hires Under 2023 Plan

Reuters
·
Jul 11

Evolus Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

THOMSON REUTERS
·
Jul 11

Analysts’ Top Healthcare Picks: Evolus (EOLS), Annovis Bio (ANVS)

TIPRANKS
·
Jul 09

Analysts Have Conflicting Sentiments on These Healthcare Companies: Evolus (EOLS), Alkermes (ALKS) and VolitionRX (VNRX)

TIPRANKS
·
Jul 08

Evolus partners with IBSA to develop and market Profhilo in the U.S.

TIPRANKS
·
Jul 08

Evolus Partners with IBSA to License, Distribute Profhilo in US

Reuters
·
Jul 08

Evolus - Agreement not Expected to Impact 2026 or 2028 Financial Targets

THOMSON REUTERS
·
Jul 08

Evolus - Under Terms, Co to Lead U.S. Regulatory Approval and Commercialization of Profhilo

THOMSON REUTERS
·
Jul 08

Evolus Announces Partnership with Ibsa to Develop and Commercialize Market-leading Profhilo® in the United States, Expanding Its Injectable Portfolio into Skin Quality

THOMSON REUTERS
·
Jul 08

Analysts Offer Insights on Healthcare Companies: TransMedics Group (TMDX) and Evolus (EOLS)

TIPRANKS
·
Jul 02